This invention belongs to the field of SNP site detection technology for guiding the use of second-generation
antipsychotic drugs. Specifically, it relates to primer and probe combinations and applications for SNP site detection to guide personalized medication of second-generation
antipsychotic drugs. The SNP site is rs17782313. The primer and probe combination includes an upstream primer SEQ ID NO:1 that specifically amplifies the wild-type T
allele, an upstream primer SEQ ID NO:2 that specifically amplifies the
mutant C
allele, a universal downstream primer SEQ ID NO:3, a wild-type probe SEQ ID NO:4, and a
mutant probe SEQ ID NO:5. This invention assesses the
genetic risk of
weight gain and metabolic disorders in patients with
mental illness after taking second-generation
antipsychotic drugs such as
risperidone,
quetiapine,
amisulpride, and
paliperidone through rapid and accurate
genotyping. It features high specificity, high accuracy, speed, simplicity, and controllable cost, and can achieve rapid single-tube
genotyping, providing key genetic evidence for the clinical development of personalized medication regimens.